Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk
Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk